Obesity Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, and others.

DelveInsight’s, “Obesity Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.

 

Key Takeaways from the Obesity Pipeline Report

  • DelveInsight’s Obesity pipeline report depicts a robust space with 100+ active players working to develop 130+ pipeline therapies for Obesity treatment.
  • The leading companies working in the Obesity Market include 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others.
  • Promising Obesity Pipeline Therapies in the various stages of development include Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others.
  • December 2023: Rhythm Pharmaceuticals Inc. announced a study of Phase 3 clinical trials for Setmelanotide. The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 60 weeks.
  • December 2023: Pfizer announced a study of Phase 1 clinical trials for Rosuvastatin and Midazolam. A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity.

 

Request a sample and discover the recent advances in Obesity Treatment Drugs @ Obesity Pipeline Report

 

In the Obesity pipeline report, detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Obesity Overview

Obesity is recognized as a chronic or non-communicable disease, a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity or body fatness which can manifest metabolically and not just concerning the size of the body.

 

Find out more about Obesity Treatment Landscape @ Drugs for Obesity Treatment

 

Obesity Emerging Drugs Profile

  • Semaglutide oral: Novo Nordisk
  • Tirzepatide: Eli Lilly and Company
  • Tesomet: Saniona
  • RZL-012: Raziel Therapeutics
  • CT-868: Carmot Therapeutics
  • EMP16: Empros Pharma
  • DD01: D&D Pharmatech
  • ZP 8396: Zealand Pharma
  • ERX-1000: ERX Pharmaceuticals

 

Obesity Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Obesity. The Obesity companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.

 

DelveInsight’s Obesity pipeline report covers around 130+ Obesity products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Obesity Pipeline Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Obesity Pipeline Therapies @ Obesity Clinical Trials Assessment

 

Scope of the Obesity Pipeline Report

  • Coverage- Global
  • Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Obesity Companies- 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, and others.
  • Obesity Pipeline Therapies- Semaglutide oral, Tirzepatide, Sibutramine/Topiramate, NNC0174-0833, Tesomet, SHR-20004, RZL-012, CT-868, PF-06882961, EMP-16, S-237648, LY3502970, ARD-101, NNC0165-1875, XW003, IBI362, TG103, Cotadutide, MBL949, PF-07081532, APHD-012, LY 3437943, HSG4112, Leucine/sildenafil, BI 456906, Pemvidutide, LY3841136, HM15136, GMA106, DD01, ZP8396, K833, NNC0480-0389, LB54640, CT-181, CB4211, CT-388, CIN-109, ERX-1000, DWP306001, SCO-094, S-309309, NO-13065, GDD3898, XW004, SCO-267, ASC41, AMG 133, LY3541105, AMG-786, HU6, BMS-963272, BI 1820237, Xla 1, Dapiglutide, PB-119, PB-718, AGTX-2004, ECC5004, Thermostem, XW017, HM 14320, TNX-2900, CF-102, XW 010, LR19020, LR19056, YH34160, NM-136, CIN 110, CIN 209, CIN 210, RSVI-301, PramExe, BC GlueExe, BC Pram GlueExe, AGEX BAT1, CLS-1, CRB-913, Tespria, AM 6545, LP-003, KT A522, JD5037, SJT4a, GL0034, TF0103, TERN-601, NEO-001, KTX 0200, ENT-03, Bimagrumab, VK2735, HUM-234, NPM 139, YHC2129, YHC2134, YHC1140, GSBR-2nd Gen, GSBR-3rd Gen, and others.

 

Dive deep into rich insights for new drugs for Obesity treatment, Visit @ Obesity Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Obesity Overview
  4. Obesity Pipeline Therapeutics
  5. Obesity Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Oral Semaglutide: Novo Nordisk
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. RZL-012: Raziel Therapeutics
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. DD01: D&D Pharmatech
  14. Drug profiles in the detailed report…..
  15. Inactive Obesity Products
  16. Obesity Key Companies
  17. Obesity Key Products
  18. Obesity Unmet Needs
  19. Obesity Market Drivers
  20. Obesity Market Barriers
  21. Obesity Future Perspectives and Conclusion
  22. Obesity Analyst Views
  23. Obesity Key Companies
  24. Appendix

 

For further information on the Obesity pipeline therapeutics, reach out @ Obesity Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, and others.

Metastatic Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 140+ pipeline drugs in the Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

  • DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 130+ active players working to develop 140+ pipeline therapies for Metastatic Colorectal Cancer treatment.
  • The leading companies working in the Metastatic Colorectal Cancer Market include Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
  • Promising Metastatic Colorectal Cancer Pipeline Therapies in the various stages of development include ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.
  • September 2023: Bristol-Myers Squibb announced a study of phase 3 clinical trials for Ipilimumab, Oxaliplatin, and Leucovorin. The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.
  • October 2023: Arcus Biosciences Inc. announced a study of Phase 1 & 2 clinical trials for AB680, Etrumadenant, Zimberelimab, and Bevacizumab. This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

 

Request a sample and discover the recent advances in Metastatic Colorectal Cancer Treatment Drugs @ Metastatic Colorectal Cancer Pipeline Report

 

In the Metastatic Colorectal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Metastatic Colorectal Cancer Overview

Cancer cells may break away from a tumor in the colon or rectum and spread to other parts of the body through the bloodstream or lymphatic system. These cells may settle and form new tumors on a different organ. Even though the cancer has spread to a new organ, it is still named after the part of the body where it originally started.

 

Find out more about Metastatic Colorectal Cancer Therapeutics Assessment @ Metastatic Colorectal Cancer Preclinical and Discovery Stage Products

 

Metastatic Colorectal Cancer Emerging Drugs Profile

  • Adagrasib (MRTX849): Mirati Therapeutics
  • QL-1203: Qilu Pharmaceutical
  • ZN-c3: Zentalis Pharmaceuticals

 

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the Metastatic Colorectal Cancer pipeline therapies. The Metastatic Colorectal Cancer companies which have their Metastatic colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.

 

Learn more about the emerging Metastatic Colorectal Cancer Pipeline Therapies @ Metastatic Colorectal Cancer Clinical Trials Assessment

 

Scope of the Metastatic Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Metastatic Colorectal Cancer Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
  • Metastatic Colorectal Cancer Pipeline Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.

 

Dive deep into rich insights for new drugs for Metastatic Colorectal Cancer Treatment, Visit @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic colorectal cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Metastatic colorectal cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. MRTX849: Mirati Therapeutics
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. AK-112: Akeso Biopharma
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. SY 5609: Syros Pharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Metastatic colorectal cancer Key Companies
  23. Metastatic colorectal cancer Key Products
  24. Metastatic colorectal cancer- Unmet Needs
  25. Metastatic colorectal cancer- Market Drivers and Barriers
  26. Metastatic colorectal cancer- Future Perspectives and Conclusion
  27. Metastatic colorectal cancer Analyst Views
  28. Metastatic colorectal cancer Key Companies
  29. Appendix

 

For further information on the Metastatic Colorectal Cancer Pipeline therapeutics, reach out to Metastatic Colorectal Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd

Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 |Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, and others.

DelveInsight’s, “Diabetes Pipeline Insights 2023” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Diabetes Pipeline Report

  • DelveInsight’s Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
  • The leading companies working in the Diabetes Market include Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
  • Promising Diabetes Pipeline Therapies in the various stages of development include LY2963016, Lantus, OAMs, ORMD-0801, Exenatide, Cotadutide, Saxagliptin, Muraglitazar, Pioglitazone, and others.
  • November 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Ertugliflozin 5 mg and Metformin. This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.
  • September 2023: Adocia announced a study of Phase 1 clinical trials for Euglycemic clamp with BC Combo THDB0207. This is a randomised, double-blind, four-period crossover euglycaemic clamp trial in subjects with type 2 diabetes. Each subject will be randomly allocated to one of four treatment sequences. Each sequence will comprise 3 different single doses of BC Combo THDB0207 (Low dose, Medium dose, and High dose) and one single dose of Humalog® Mix25.

 

Request a sample and discover the recent advances in Diabetes Treatment Drugs @ Diabetes Pipeline Outlook Report

 

The Diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Diabetes drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Diabetes clinical trial landscape.

 

Diabetes Overview

Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas.

 

Find out more about Diabetes Treatment Landscape @ Drugs for Diabetes Treatment

 

Diabetes Emerging Drugs Profile

  • Enavogliflozin – Daewoong
  • Golimumab – Janssen Biotech

 

Diabetes Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the therapies for Diabetes. The Diabetes companies which have their Diabetes drug candidates in the most advanced stage, i.e. phase III include, Daewoong.

 

DelveInsight’s Diabetes Pipeline Report covers around 200+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

 

Diabetes Pipeline Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Learn more about the emerging Diabetes Pipeline Therapies @ Diabetes Clinical Trials Assessment

 

Scope of the Diabetes Pipeline Report

  • Coverage- Global
  • Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Diabetes Companies- Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
  • Diabetes Pipeline Therapies- LY2963016, Lantus, OAMs, ORMD-0801, Exenatide, Cotadutide, Saxagliptin, Muraglitazar, Pioglitazone, and others.

 

Dive deep into rich insights for new drugs for Diabetes treatment, Visit @ Diabetes Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetes: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diabetes – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Diabetes Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Enavogliflozin: Daewoong
  11. Mid Stage Products (Phase II)
  12. Golimumab: Janssen Biotech
  13. Early Stage Products (Phase II/I)
  14. IMCY-0098: ImCyse
  15. Pre-clinical and Discovery Stage Products
  16. ENT-001: Enthera
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Diabetes Key Companies
  20. Diabetes Key Products
  21. Diabetes- Unmet Needs
  22. Diabetes- Market Drivers and Barriers
  23. Diabetes- Future Perspectives and Conclusion
  24. Diabetes Analyst Views
  25. Diabetes Key Companies
  26. Appendix

 

For further information on the Diabetes pipeline therapeutics, reach out @ Diabetes Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 |Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, and others.

Type 2 Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, and others.

DelveInsight’s, “Type 2 Diabetes Mellitus Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type 2 Diabetes mellitus pipeline landscape. It covers the Type 2 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 2 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Type 2 Diabetes Pipeline Report

  • DelveInsight’s Type 2 Diabetes pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Type 2 Diabetes treatment.
  • The leading companies working in the Type 2 Diabetes Market include Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Daiichi Sankyo Company, Halozyme Therapeutics, Saniona, Novartis, Pfizer, Merck Sharp & Dohme Corp., Mylan, Nordic Bioscience A/S, KeyBioscience AG, Adocia, Jiangsu Hengrui Medicine, Bristol myers Suibb, Phenomix, Forest Laboratories, ACADIA Pharmaceuticals, Hanmi Pharmaceuticals, Cytogel, Ligand Pharmaceuticals, Arthritis Innovation Corporation, Astellas Pharma, IItoo Pharma, Medspace Inc., Oramed Ltd., Flexion Therapeutics, Integrium, AbbVie, and others.
  • Promising Type 2 Diabetes Pipeline Therapies in the various stages of development include Muraglitazar, Pioglitazone, Cotadutide, ORMD-0801 (qd), glargine, detemir, saxagliptin, sitagliptin, and others.
  • November 2023: Prokidney announced a study of Phase 3 clinical trials for Renal Autologous Cell Therapy (REACT). The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
  • November 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Ertugliflozin 5 mg and Metformin. This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.

 

Request a sample and discover the recent advances in Type 2 Diabetes Treatment Drugs @ Type 2 Diabetes Pipeline Outlook Report

 

The Type 2 Diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Type 2 Diabetes drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Type 2 Diabetes clinical trial landscape.

 

Type 2 Diabetes Overview

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. Diabetes mellitus are of three types Type1, Type 2 and Gestational Diabetes.

 

Find out more about Type 2 Diabetes Treatment Landscape @ Drugs for Type 2 Diabetes Treatment

 

Type 2 Diabetes Emerging Drugs Profile

  • Sotagliflozin: Lexicon Pharmaceuticals
  • ORMD0801: Oramed Pharmaceuticals
  • LY3209590-Eli lily and Company
  • HM12460A: Hanmi Pharmaceuticals
  • HM14220:Hanmi Pharmaceuticals

 

Type 2 Diabetes Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Postoperative Pain. The Type 2 Diabetes companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Lexicon Pharmaceuticals.

 

DelveInsight’s Type 2 Diabetes pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Type 2 Diabetes mellitus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule
  • Product Type

 

Learn more about the emerging Type 2 Diabetes Pipeline Therapies @ Type 2 Diabetes Clinical Trials Assessment

 

Scope of the Type 2 Diabetes Pipeline Report

  • Coverage- Global
  • Type 2 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Type 2 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Type 2 Diabetes Companies- Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Daiichi Sankyo Company, Halozyme Therapeutics, Saniona, Novartis, Pfizer, Merck Sharp & Dohme Corp., Mylan, Nordic Bioscience A/S, KeyBioscience AG, Adocia, Jiangsu Hengrui Medicine, Bristol myers Suibb, Phenomix, Forest Laboratories, ACADIA Pharmaceuticals, Hanmi Pharmaceuticals, Cytogel, Ligand Pharmaceuticals, Arthritis Innovation Corporation, Astellas Pharma, IItoo Pharma, Medspace Inc., Oramed Ltd., Flexion Therapeutics, Integrium, AbbVie, and others.
  • Type 2 Diabetes Pipeline Therapies- Muraglitazar, Pioglitazone, Cotadutide, ORMD-0801 (qd), glargine, detemir, saxagliptin, sitagliptin, and others.

 

Dive deep into rich insights for new drugs for Type 2 Diabetes treatment, Visit @ Type 2 Diabetes Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Type 2 Diabetes mellitus: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Type 2 Diabetes mellitus – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Sotagliflozin: Lexicon Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. LY3209590: Eli lily and Company
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. HM12460A: Hanmi Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. HM14220: Hanmi Pharmaceuticals
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Type 2 Diabetes mellitus- Key Companies
  21. Type 2 Diabetes mellitus- Key Products
  22. Type 2 Diabetes mellitus – Unmet Needs
  23. Type 2 Diabetes mellitus – Market Drivers and Barriers
  24. Type 2 Diabetes mellitus – Future Perspectives and Conclusion
  25. Type 2 Diabetes mellitus Analyst Views
  26. Type 2 Diabetes mellitus Key Companies
  27. Appendix

 

For further information on the Type 2 Diabetes pipeline therapeutics, reach out @ Type 2 Diabetes Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Type 2 Diabetes Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Hanmi Pharmaceuticals, Sanofi, Eli lily and Company, AstraZeneca, NovoNordisk, Noxxon Pharma AG, and others.

Steel Wire Rope & Plastic Rope Market to a Projected Valuation of $17.5 Billion by 2026| MarketsandMarkets™

“Browse 270 market data Tables and 58 Figures spread through 257 Pages and in-depth TOC on “Steel Wire Rope & Plastic Rope Market””
Steel Wire Rope & Plastic Rope Market by Type of Lay (Regular Lay, Lang Lay), Material Type (PP, PET, Nylon, HMPE, Specialty fibers), Application (Marine & Fishing, Sports & Leisure, Oil & Gas, Industrial & Crane) Region – Global Forecast to 2026

The global steel wire rope & plastic rope market size was USD 11.9 billion in 2021 and is expected to reach USD 17.5 billion by 2026, projecting a CAGR of 8.0% between 2021 and 2026. Steel wire ropes & plastic ropes are increasingly used in the marine & fishing, sports & leisure, oil & gas, industrial & crane, mining, construction, and other end-use applications. However, the outbreak of COVID-19 has created ripples across various application industries leading to reduced demand for steel wire ropes & plastic ropes. Due to the lockdown scenario in Europe and North America, the demand for steel wire ropes & plastic ropes from oil & gas, industrial & crane, mining, construction, and other applications have declined sharply in 2020.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162936381 

Steel wire ropes and plastic ropes have high applicability in the marine & fishing and mining sectors. Plastic ropes are less prone to corrosion and have floating properties that make them suitable for use in fishing activities. In mining applications, steel wire ropes are preferred due to their high load-bearing strength. In APAC, the fishing and mining sectors are among the booming sectors, especially in countries such as China, Indonesia, Japan, and India. APAC led the total aquaculture production and accounted for 89% of the global aquaculture production in 2013. In addition, APAC has the world’s largest mineral reserves. This is expected to help the steel wire ropes and plastic ropes manufacturers with immense growth opportunities in the region.

Steel wire ropes and plastic ropes have a higher strength-to-weight ratio, which is an important factor for various applications specially in the marine and fishing sector. Plastic ropes are used for various lifting and towing purposes in the marine industry. The property of plastic ropes to float in water makes them appropriate for use in this industry. Plastic ropes are used by tankers and cargo vessels, cruise ships and ferries, tug and salvage operators, offshore oil & gas contractors, naval ships, and port authorities for mooring, towing, and safety lines.

Over the past years, steel wire ropes & plastic ropes manufacturers have strengthened their position in the global steel wire rope & plastic rope market by adopting expansions, partnerships, agreements, new product/technology launches, joint ventures, contracts, and mergers & acquisitions. However, owing to lockdown announced by several countries in 2020, the demand for steel wire ropes & plastic ropes from oil & gas, mining, construction, and other end-use applications has declined sharply, which resulted in declined demand for steel wire ropes & plastic ropes.

The major manufacturers profiled in this report include Cortland Limited (US), WireCo WorldGroup Inc., (US), Samson Rope Technologies (US), Southern Ropes (South Africa) and English Braids Ltd. (UK), are some of the key players in the steel wire rope & plastic rope market. Marlow Ropes (UK), Teufelberger Holding AG (Austria), Bekaert SA (Belgium), Usha Martin (India), Gustav Wolf (Germany), and among others.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=162936381  

Cortland Limited (US) works through its subsidiaries: Cortland Cable (US), Cortland Puget Sound Rope (US), Cortland Fibron BX (UK), and Cortland Selantic (Norway). Cortland Limited operates as a subsidiary of Actuant Corporation (US), a diversified industrial company with operations in more than 30 countries worldwide. The company provides custom solutions and offers its products to various industries such as oil & gas, marine, aerospace & defense, and medical. Its product line is categorized into synthetic rope & strength members, lifting slings & tethers, umbilical, electro-optical-mechanical cables, and medical textile & strength members.

WireCo WorldGroup Inc., (US)  is one of the leading manufacturers of steel wire & synthetic ropes, fabricated products, specialty steel wires, synthetic yarns, and electromechanical cables. It has three business segments—ropes, specialty wires, and engineered products. The company markets its products under multiple brands: Union, MacWhyte, Casar, Camesa, Oliveira, Wireline Works, Phillystran, Lankhorst Ropes and Yarns, Drumet, and US Reel.

The steel wire rope & plastic rope business of these companies is severely affected due to the outbreak of COVID – 19 pandemic. Reduced demand for steel wire ropes & plastic ropes from several applications and disruption in the supply chain have compelled the steel wire ropes & plastic ropes manufacturing companies to operate at partial capacities. However, several steel wire rope & plastic rope manufacturers have focused their concentration on new product development. These developments, coupled with end-use applications resuming their operations at full capacities, would create demand for steel wire ropes & plastic ropes during the forecast period.

Read Our Trending Press Release Below:

Liquid Adhesives Market– Global Forecast to 2025

Glass Fiber Yarn Market– Global Forecast to 2027

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/steel-wire-plastic-rope-market-162936381.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Steel Wire Rope & Plastic Rope Market to a Projected Valuation of $17.5 Billion by 2026| MarketsandMarkets™

Metagenomic Sequencing Market worth $4.5 billion in 2028

“The European market is the second-largest metagenomic sequencing market globally, mainly due to factors such as increasing number of research projects, especially in the field of soil microbiome metagenomics, in the region.”
Browse 226 market data Tables and 44 Figures spread through 266 Pages and in-depth TOC on “Metagenomic Sequencing Market by Product & Services(Reagent, Consumables, Instrument), Workflow (Sample Preparation, Sequencing), Technology(16S rRNA, Shotgun, Whole-genome), Application (Drug Discovery, Diagnostic, Industrial) – Global Forecast to 2028

Metagenomic Sequencing Market in terms of revenue was estimated to be worth $2.0 Billion in 2023 and is poised to reach $4.5 Billion by 2028, growing at a CAGR of 17.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of the metagenomic sequencing market are frequenct technological innovations in the NGS platforms and increasing understanding of the wide as well as significant applications of metagenomics in several fields. However, budget constraints faced by developing countries due to lack of government, private support in terms of funding, infrastructure is expected to restrain market growth to a certain extent.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=60408643

Reagents & Consumables subsegment accounted for the largest share of the metagenomic sequencing market by product & service

Among the product & service, the metagenomic sequencing market is segmented reagents & consumables, instruments, sequencing services and analysis & data interpretation solutions. In 2023, the reagents and consumables segment accounted for the largest share of the metagenomic sequencing market by product & service. Growth in this market segment can be attributed to factors such as commercialization of reagents and kits and repetitive purchase of sequencing reagents by demand side entities among others.

Drug discovery is the fastest-growing segment of the metagenomic sequencing market by applications

Among the applications, the metagenomic sequencing market is segmented into drug discovery, clinical diagnostics, soil microbiome applications, industrial applications, ecological & environmental applications, veterinary applications, and other applications. In 2023, the drug discovery segment accounted for the fastest-growing share of the usage segment of metagenomic sequencing market. Growth in this market segment can be attributed to one of the major factors which is the growing number of research activities for development of new drugs.

Europe: The second-largest region in the metagenomic sequencing market.

The European market is the second-largest metagenomic sequencing market globally, mainly due to factors such as increasing number of research projects, especially in the field of soil microbiome metagenomics, in the region. Moreover, Europe is considered a major hub for metagenomic sequencing players and organizations.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=60408643

Metagenomic Sequencing Market Dynamics:

Drivers:

     1.  Continuous technological innovations in NGS platforms

          a.  iSeq 100 System

          b.  Ion GeneStudio S5

     2.  Initiatives and funding from government & private bodies for large-scale sequencing projects

     3.  Declining costs of genome sequencing

     4.  Significant applications of metagenomics in various fields

Restraints:

  1. End-user budget constraints in developing countries

Opportunities:

  1. NGS data analysis using big data

Challenges:

  1. Challenges associated with metagenomic NGS

Key Market Players:

The market for metagenomic sequencing is consolidated, with key players strategizing to capture the market. Prominent players in the metagenomic sequencing market are Illumina, Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), and Oxford Nanopore Technologies Plc. (UK) among others.

Recent Developments:

  • In September 2022, Illumina, Inc. (US) launched the NovaSeq X series production-scale sequencers, which are capable of generating more than 20,000 whole genomes per year (which is 2.5 times the throughput of prior sequencers from Illumina).
  • In September 2021, Thermo Fisher Scientific, Inc. (US) and AstraZeneca (UK) co-developed an NGS-based companion diagnostic. The collaboration was focused on commercializing NGS-based diagnostics in Russia.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=60408643

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/metagenomic-sequencing-market-60408643.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metagenomic Sequencing Market worth $4.5 billion in 2028

Near infrared imaging Market worth $1.6 billion by 2028

“The Asia Pacific near infrared imaging market is estimated to register a significant growth from 2023 to 2028. The increasing patient population, rising geriatric population, rapid economic growth and increasing disposable income are driving the market growth in APAC countries.”
Stryker is a leading medical technology company and a key player in the near-infrared imaging market. It offers a diverse array of innovative products and services for orthopedic, medical, surgical, and neurotechnology applications that help improve patient and hospital outcomes.

Near infrared imaging Market in terms of revenue was estimated to be worth $1.0 billion in 2023 and is poised to reach $1.9 billion by 2028, growing at a CAGR of 14.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market include rising patient population, various chronic diseases, and technological advancements along with the increasing adoption of hybrid NIR imaging.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174869738

Product segment to register significant growth rate over the forecast period of 2023-2028

Based on the product, the global the near-infrared imaging market is segmented into NIR devices, NIR imaging agents/probes and NIR dyes. The NIR device segment is anticipated to register the highest growth rate over the forecast period. The NIR device segment accounted for the highest share of the near infrared imaging market in 2022.

Procedure segment to register significant growth rate over the forecast period of 2023-2028

Based on the procedure, the near-infrared imaging market is segmented into cancer surgeries, gastrointestinal surgeries, cardiovascular surgeries, plastic/reconstructive surgeries, and ob/gyn surgeries and other applications. The cancer surgeries segment is anticipated to register the highest growth rate over the forecast period. The cancer surgeries segment accounted for the highest share of the near infrared imaging market in 2022.

Preclinical segment accounted for the largest share of the near infrared imaging market, by application in 2022.

Based on application, the global the near-infrared imaging market is segmented into preclinical imaging, clinical imaging, and medical imaging. Preclinical applications accounted for the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.

Factors such as the rising incidence of cancer cases, the growing geriatric population, and the launch of integrated modalities drive the growth of PET products.

The hospital and clinics segment accounted for the largest share of the near infrared imaging market, by end user, in 2022

Based on end user, the near-infrared imaging market is segmented into hospitals & clinics, research laboratories, and pharmaceutical & biotechnology companies. The hospital and clinic segment accounts for the largest share of the market in 2022. Factors attributing to the share of this particular are increasing cancer incidences and increasing number of dermatological surgeries performed in hospitals and clinics are driving the growth of this segment.

The Asia Pacific market to register a significant growth in the market during the forecast period

The Asia Pacific near infrared imaging market is estimated to register a significant growth from 2023 to 2028. The increasing patient population, rising geriatric population, rapid economic growth and increasing disposable income are driving the market growth in APAC countries. This region is having a rise in healthcare investment and expenditure, offering significant growth opportunities for the key players.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174869738

Near infrared imaging Market Dynamics:

Drivers:

  1. Increasing number of surgical procedures

Restraints:

  1. High Capital and Operational Cost

Opportunities:

  1. Use of blockchain in imaging

Challenges:

  1. Hospital budget cuts

Key Market Players:

As of 2022, prominent players in the near infrared imaging market are Stryker (US), KARL STORZ SE & Co. KG (Germany), Carl Zeiss Meditec AG (Germany), Leica Microsystems (US), Olympus Corporation (Japan), PerkinElmer, Inc. (US), LI-COR, Inc. (US), and Medtronic (Ireland),

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=174869738

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/near-infrared-imaging-market-174869738.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Near infrared imaging Market worth $1.6 billion by 2028

Family Home Care of Central FL Continues Offering Exceptional Companion Care in Winter Park

Family Home Care of Central FL continues to offer exceptional companion care in Winter Park, FL. Owner Jarod Carter emphasizes the importance of companionship for seniors’ well-being, providing personalized care with emotional and social support. Their services focus on seniors’ independence, dignity, and connection, addressing the growing need for quality care. Google us at https://familyhomecarecf.com for more information.

Winter Park, FL – Family Home Care of Central FL, a leading provider of non-medical home care, proudly announces the ongoing provision of its exceptional companion care services in Winter Park, FL. This initiative responds to the growing need for comprehensive non-medical home care among families and residents in the region.

Jarod Carter, the owner of Family Home Care of Central FL, highlights the company’s dedication. “In our ongoing commitment to the Winter Park community, Family Home Care of Central FL is honored to continue offering exceptional companion care services,” stated Carter. “Our approach deeply understands the significance of companionship on seniors’ overall well-being. We are devoted to assisting with daily tasks and providing emotional and social support, ensuring our clients enjoy a fulfilling and enriched life. Our team’s unwavering commitment to forming meaningful connections with each individual distinguishes us in positively transforming the lives of seniors in Winter Park.”

The company’s commitment extends beyond basic care, focusing on each client’s unique needs and preferences. By delivering personalized care, Family Home Care of Central FL ensures that every senior in their care maintains a sense of independence and dignity. The services promote physical well-being and mental and emotional health, contributing to a more vibrant and connected community in Winter Park.

In an era where the senior population is rapidly growing, the demand for quality companion care is more crucial than ever. Family Home Care of Central FL’s continued service expansion in Winter Park demonstrates its responsiveness to this demographic shift and its dedication to being at the forefront of quality senior care.

For more information about Family Home Care of Central FL and their companion care in Winter Park, please visit their website at https://familyhomecarecf.com 

About Family Home Care of Central FL:

Over the years, Family Home Care of Central FL has built a reputation for its holistic approach, seamlessly integrating health and wellness services with emotional and social support, enriching the lives of seniors and their families in the Casselberry community.

Media Contact
Company Name: Family Home Care of Central FL
Contact Person: Jarod Carter
Email: Send Email
Phone: +14076414306
Address:1326 Palmetto Ave
City: Winter Park
State: FL
Country: United States
Website: https://familyhomecarecf.com/

Waste to Energy Market to Witness Steady Growth at 7.5% CAGR| Mitsubishi Heavy Industries Ltd, Waste Management Inc, A2A SpA, Veolia Environment SA, Hitachi Zosen Corp

“Waste to Energy (WTE) Marke”
The Global Waste to Energy Market is poised for substantial growth, with an estimated increase of 7.5% anticipated over the forecast period from 2023 to 2030.

A new business intelligence report released by USD Analytics with the title “Global Waste to Energy Market Report 2030” has abilities to rise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The Global Waste to Energy Market Report offers energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative details. Some of the key players profiled in the study are Mitsubishi Heavy Industries Ltd, Waste Management Inc, A2A SpA, Veolia Environment SA, Hitachi Zosen Corp, MVV Energie AG, Martin GmbH, Babcock & Wilcox Enterprises Inc, China Jinjiang Environment Holding Co. Ltd, Suez Group, Xcel Energy Inc, Wheelbarrow Technologies Holdings Inc, Covanta Holding Corp, China Everbright Group.

 

Avail Limited Period Offer of 25% Instant Discount @: https://www.usdanalytics.com/discount-request/9415

 

Market Overview of Global Waste to Energy

Waste-to-energy (WTE) represents a sustainable approach to managing various types of waste by converting them into usable forms of energy, such as electricity or heat. This involves employing different technologies like incineration, anaerobic digestion, and gasification. Incineration burns waste at high temperatures, utilizing the generated heat to produce electricity. Anaerobic digestion decomposes organic waste to generate biogas, mainly composed of methane, usable for electricity generation or renewable natural gas. Gasification converts solid waste into synthetic gas (syngas), applicable for electricity generation or biofuel production. WTE not only reduces the environmental impact of waste disposal by minimizing landfill use but also contributes to lowering greenhouse gas emissions. It plays a crucial role in comprehensive waste management, complementing recycling efforts. The primary outcomes include electricity generation and heat recovery, with the potential to diversify the energy mix and enhance overall energy efficiency. Ongoing technological advancements aim to improve efficiency and expand the range of convertible waste materials. Despite its benefits, challenges such as public perception and regulatory considerations need careful consideration. Waste-to-energy aligns with the principles of a circular economy, extracting value from waste materials and promoting sustainability in global resource management practices. As technology advances, waste-to-energy processes are poised to play an increasingly significant role in a more sustainable and circular approach to waste and energy management.

 

This study mainly helps understand which market segments or Region or Country they should focus on in coming years to channel their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in-depth analysis of the major vendors/key players in the market. 

 

The Global Waste to Energy Market is poised for substantial growth, with an estimated increase of 7.5% anticipated over the forecast period from 2023 to 2030.

 

Furthermore, the years considered for the study are as follows: Historical year – 2018-2022 Base year – 2022 Forecast period** – 2023 to 2030 [** unless otherwise stated]

 

The titled segments and sub-sections of the market are illuminated below:

by Technology (Physical, Thermal, Biological, Others) By Application (Power Plant, Heating Plant, Others)

 

Top Players in the Market are: Mitsubishi Heavy Industries Ltd, Waste Management Inc, A2A SpA, Veolia Environment SA, Hitachi Zosen Corp, MVV Energie AG, Martin GmbH, Babcock & Wilcox Enterprises Inc, China Jinjiang Environment Holding Co. Ltd, Suez Group, Xcel Energy Inc, Wheelbarrow Technologies Holdings Inc, Covanta Holding Corp, China Everbright Group

 

Region Included are: North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy) & Other Country (Middle East, Africa, GCC)

 

Free Sample Report + All Related Graphs & Charts @:  https://www.usdanalytics.com/sample-request/9415

 

Important Features that are under offering & key highlights of the report: – Detailed overview of Waste to Energy market – Changing market dynamics of the industry – In-depth market segmentation by Type, Application etc – Historical, current and projected market size in terms of volume and value – Recent industry trends and developments – Competitive landscape of Waste to Energy market – Strategies of key players and product offerings – Potential and niche segments/regions exhibiting promising growth – A neutral perspective towards Waste to Energy market performance – Must-have information for market players to sustain and enhance their market footprint

 

Read the Detailed Index of the full Research Study at @  https://www.usdanalytics.com/industry-reports/waste-to-energy-market

 

Research Objectives:– Focuses on the key manufacturers, to define, pronounce and examine the value, sales volume, market share, market competition landscape, SWOT analysis, and development plans in the next few years. – To share comprehensive information about the key factors influencing the growth of the market (opportunities, drivers, growth potential, industry-specific challenges and risks).

– To analyze the with respect to individual future prospects, growth trends and their involvement to the total market. – To analyze reasonable developments such as agreements, expansions new product launches, and acquisitions in the market. – To deliberately profile the key players and systematically examine their growth strategies. FIVE FORCES & PESTLE ANALYSIS: In order to better understand market conditions five forces analysis is conducted that includes the Bargaining power of buyers, Bargaining power of suppliers, Threat of new entrants, Threat of substitutes, and Threat of rivalry. • Political (Political policy and stability as well as trade, fiscal, and taxation policies) • Economical (Interest rates, employment or unemployment rates, raw material costs, and foreign exchange rates) • Social (Changing family demographics, education levels, cultural trends, attitude changes, and changes in lifestyles) • Technological (Changes in digital or mobile technology, automation, research, and development) • Legal (Employment legislation, consumer law, health, and safety, international as well as trade regulation and restrictions) • Environmental (Climate, recycling procedures, carbon footprint, waste disposal, and sustainability)

 

Buy the Latest Detailed Report @ https://www.usdanalytics.com/payment/report-9415

 Key questions answered• Who are the Leading key players and what are their Key Business plans in the Global Waste to Energy market? • What are the key concerns of the five forces analysis of the Global Waste to Energy market? • What are the different prospects and threats faced by the dealers in the Global Waste to Energy market? • What are the strengths and weaknesses of the key vendors?

 

Thanks for reading this article; you can also get individual chapter-wise sections or region-wise report versions like North America, Europe, or Asia.

 

About Author: USD Analytics is a leading information and analytics provider for customers across industries worldwide. Our high-quality research publications are connected market. Intelligence databases and consulting services support end-to-end support our customer research needs.

Media Contact
Company Name: USD Analytics
Contact Person: Harry James
Email: Send Email
Phone: +1 213-510-3499
Country: India
Website: https://www.usdanalytics.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Waste to Energy Market to Witness Steady Growth at 7.5% CAGR| Mitsubishi Heavy Industries Ltd, Waste Management Inc, A2A SpA, Veolia Environment SA, Hitachi Zosen Corp

Cloud Robotics Market to Develop New Growth Story | IBM, Google, Microsoft

We help our customers settle on more intelligent choices to accomplish quick business development. Our strength lies in the unbeaten diversity of our global market research teams, innovative research methodologies, and unique perspective that merge seamlessly to offer customized solutions for your every business requirement.

A new business intelligence report released by USD Analytics with title “Global Cloud Robotics Market Report 2030 ” has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The Global Cloud Robotics Market Report offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are IBM (United States), Amazon Robotics (United States), Google (United States), Huawei (China), C2RO (Canada), CloudMinds (United States), Hit Robot Group (United States), Rapyuta Robotics (Japan), Ortelio (United Kingdom), Microsoft (United States), V3 Smart Technologies (Singapore)

Free Sample Report + All Related Graphs & Charts @ : https://www.usdanalytics.com/sample-request/10253

Definition:

Cloud computing, cloud storage, and other Internet technologies form the foundation of cloud robotics, an emerging discipline of robotics focused on the advantages of unified infrastructure and shared services. It makes it possible for robots to take advantage of the robust networking, storage, and processing capabilities of contemporary data centers. It also lessens reliance on bespoke middleware and eliminates maintenance and update overhead. Over the course of the forecast period, a robust growth rate is anticipated in the worldwide cloud robotics market. Growing use of robotics-as-a-service (RaaS) and increasing use of cloud-based technologies for automation across various end-use sectors are anticipated to be two of the key drivers driving the market’s growth. However, throughout the next several years, the market’s growth is anticipated to somewhat fall; however, once the COVID-19 epidemic is ended, it is anticipated to develop at a strong pace once more.

The Global Cloud Robotics Market Size is estimated to register 27.5% growth over the forecast period from 2023 to 2030.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market. 

Furthermore, the years considered for the study are as follows:

Historical year – 2018-2022

Base year – 2022

Forecast period** – 2023 to 2030 [** unless otherwise stated]

The titled segments and sub-section of the market are illuminated below: Component (Software, Services), By Service Model (IaaS, Paas, SaaS), By Application (Industrial Robots, Customer Robots, Military Robots, Commercial Robots), By End-User (Manufacturing, Defence, BFSI, Transportation and Logistics, Healthcare, Retail, Others)

Top Players in the Market are: IBM (United States), Amazon Robotics (United States), Google (United States), Huawei (China), C2RO (Canada), CloudMinds (United States), Hit Robot Group (United States), Rapyuta Robotics (Japan), Ortelio (United Kingdom), Microsoft (United States), V3 Smart Technologies (Singapore)

Region Included are: North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy) & Other Country (Middle East, Africa, GCC)

Avail Limited Period Offer of 25% Instant Discount @: https://www.usdanalytics.com/discount-request/10253

Important Features that are under offering & key highlights of the report:

– Detailed overview of Cloud Robotics market – Changing market dynamics of the industry – In-depth market segmentation by Type, Application etc – Historical, current and projected market size in terms of volume and value – Recent industry trends and developments – Competitive landscape of Cloud Robotics market – Strategies of key players and product offerings – Potential and niche segments/regions exhibiting promising growth – A neutral perspective towards Cloud Robotics market performance – Must-have information for market players to sustain and enhance their market footprint

Read Detailed Index of full Research Study at @: https://www.usdanalytics.com/industry-reports/cloud-robotics-market

Research Objectives:– Focuses on the key manufacturers, to define, pronounce and examine the value, sales volume, market share, market competition landscape, SWOT analysis, and development plans in the next few years. – To share comprehensive information about the key factors influencing the growth of the market (opportunities, drivers, growth potential, industry-specific challenges and risks).

– To analyze the with respect to individual future prospects, growth trends and their involvement to the total market. – To analyze reasonable developments such as agreements, expansions new product launches, and acquisitions in the market. – To deliberately profile the key players and systematically examine their growth strategies.

FIVE FORCES & PESTLE ANALYSIS: In order to better understand market conditions five forces analysis is conducted that includes the Bargaining power of buyers, Bargaining power of suppliers, Threat of new entrants, Threat of substitutes, and Threat of rivalry. • Political (Political policy and stability as well as trade, fiscal, and taxation policies) • Economical (Interest rates, employment or unemployment rates, raw material costs, and foreign exchange rates) • Social (Changing family demographics, education levels, cultural trends, attitude changes, and changes in lifestyles) • Technological (Changes in digital or mobile technology, automation, research, and development) • Legal (Employment legislation, consumer law, health, and safety, international as well as trade regulation and restrictions) • Environmental (Climate, recycling procedures, carbon footprint, waste disposal, and sustainability)

Buy the Latest Detailed Report @: https://www.usdanalytics.com/payment/report-10253

Key questions answered

• Who are the Leading key players and what are their Key Business plans in the Global Cloud Robotics market?

• What are the key concerns of the five forces analysis of the Global Cloud Robotics market?

• What are different prospects and threats faced by the dealers in the Global Cloud Robotics market?

• What are the strengths and weaknesses of the key vendors?

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Media Contact
Company Name: USD Analytics
Contact Person: Harry James
Email: Send Email
Phone: +1 213-510-3499
State: Telangana
Country: India
Website: https://www.usdanalytics.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cloud Robotics Market to Develop New Growth Story | IBM, Google, Microsoft